Catalog # |
Size |
Price |
|
---|---|---|---|
003-53 | 100 µg | $299 |
Ser-Ser-Arg-Arg-Cys-Val-Arg-Leu-His-Glu-Ser-Cys-Leu-Gly-Gln-Gln-Val-Pro-Cys-Cys-Asp-Pro-Cys-Ala-Thr-Cys-Tyr-Cys-Arg-Phe-Phe-Asn-Ala-Phe-Cys-Tyr-Cys-Arg-Lys-Leu-Gly-Thr-Ala-Met-Asn-Pro-Cys-Ser-Arg-Thr-NH2
|
Contains 5 disulfide bridges, precise positions are undetermined
|
5676.66 | |
| ≥ 95% |
| Exhibits correct molecular weight |
| Soluble in water |
|
Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles. |
| White powder |
| Each vial contains 100 µg of NET peptide. |
| View/Download(PDF) |
Repeated agouti related peptide (83-132) injections inhibit cocaine-induced locomotor sensitisation, but not via the nucleus accumbens.
Alserda E, Adan RA, Ramakers GM. Eur J Pharmacol. 2013;719(1-3):187-91.
Melanocortin 3/4 receptors in paraventricular nucleus modulate sympathetic outflow and blood pressure.
Li P, Cui BP, Zhang LL, Sun HJ, Liu TY, Zhu GQ. Exp Physiol. 2013;98(2):435-43.
The melanocortin antagonist AgRP (83-132) increases appetitive responding for a fat, but not a carbohydrate, reinforcer.
Tracy AL, Clegg DJ, Johnson JD, Davidson TL, Benoit SC. Pharmacol Biochem Behav. 2008;89(3):263-71.
Role of third intracellular loop of the melanocortin 4 receptor in the regulation of constitutive activity.
Kim DH, Shin SW, Baik JH. Biochem Biophys Res Commun. 2008;365(3):439-45.
Differential activation of the sympathetic innervation of adipose tissues by melanocortin receptor stimulation.
Brito MN, Brito NA, Baro DJ, Song CK, Bartness TJ. Endocrinology. 2007;148(11):5339-47.
Antibodies against the melanocortin-4 receptor act as inverse agonists in vitro and in vivo.
Peter JC, Nicholson JR, Heydet D, Lecourt AC, Hoebeke J, Hofbauer KG. Am J Physiol Regul Integr Comp Physiol. 2007;292(6):R2151-8.
Effects of in vivo and in vitro administration of ghrelin, leptin and neuropeptide mediators on pulsatile gonadotrophin-releasing hormone secretion from male rat hypothalamus before and after puberty.
Lebrethon MC, Aganina A, Fournier M, Gérard A, Parent AS, Bourguignon JP. J Neuroendocrinol. 2007;19(3):181-8.
Constitutive traffic of melanocortin-4 receptor in Neuro2A cells and immortalized hypothalamic neurons.
Mohammad S, Baldini G, Granell S, Narducci P, Martelli AM, Baldini G. J Biol Chem. 2007;282(7):4963-74.
C-terminal part of AgRP stimulates insulin secretion through calcium release in pancreatic beta Rin5mf cells.
Kim HS, Yumkham S, Lee HY, et al. Neuropeptides. 2005;39(4):385-93.
Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states.
Nickolls SA, Fleck B, Hoare SR, Maki RA. J Pharmacol Exp Ther. 2005;313(3):1281-8.
Effects of melanocortin receptor activation and blockade on ethanol intake: a possible role for the melanocortin-4 receptor.
Navarro M, Cubero I, Chen AS, et al. Alcohol Clin Exp Res. 2005;29(6):949-57.
Expression of agouti-related protein (AgRP) in the hypothalamus and adrenal gland of the duck ( Anas platyrhynchos).
Mirabella N, Esposito V, Squillacioti C, De luca A, Paino G. Anat Embryol. 2004;209(2):137-41.
Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese finnish children and adults.
Valli-jaakola K, Lipsanen-nyman M, Oksanen L, et al. J Clin Endocrinol Metab. 2004;89(2):940-5.
Agouti-related protein stimulates the hypothalamic-pituitary-adrenal (HPA) axis and enhances the HPA response to interleukin-1 in the primate.
Xiao E, Xia-zhang L, Vulliémoz NR, Ferin M, Wardlaw SL. Endocrinology. 2003;144(5):1736-41.
Effect of Agouti-related protein on development of conditioned taste aversion and oxytocin neuronal activation.
Wirth MM, Olszewski PK, Levine AS, Giraudo SQ. Neuroreport. 2002;13(10):1355-8.
Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects.
Goldstone AP, Unmehopa UA, Bloom SR, Swaab DF. J Clin Endocrinol Metab. 2002;87(2):927-37.
Immediate and prolonged patterns of Agouti-related peptide-(83--132)-induced c-Fos activation in hypothalamic and extrahypothalamic sites.
Hagan MM, Benoit SC, Rushing PA, Pritchard LM, Woods SC, Seeley RJ. Endocrinology. 2001;142(3):1050-6.
AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor.
Nijenhuis WA, Oosterom J, Adan RA. Mol Endocrinol. 2001;15(1):164-71.
Long-term orexigenic effects of AgRP-(83---132) involve mechanisms other than melanocortin receptor blockade.
Hagan MM, Rushing PA, Pritchard LM, et al. Am J Physiol Regul Integr Comp Physiol. 2000;279(1):R47-52.
Identification of receptors for neuromedin U and its role in feeding.
Howard AD, Wang R, Pong SS, et al. Nature. 2000;406(6791):70-4.
A synthetic human Agouti-related protein-(83-132)-NH2 fragment is a potent inhibitor of melanocortin receptor function.
Quillan JM, Sadée W, Wei ET, Jimenez C, Ji L, Chang JK. FEBS Lett. 1998;428(1-2):59-62.
Social Network Confirmation